Why Gilead paid $1.68B but left the heavy lifting to Galapagos

Gilead Sciences, the Foster City drugmaker best known for antivirals and now pushing deeper into inflammation, is paying a startling amount for Ouro Medicines, a young autoimmune biotech. But the real story is not the sticker price. It is the structure. On paper, Gilead said it will buy Ouro for $1.675 billion upfront and up to $500 million in milestones, adding OM336, or gamgertamig, a clinical-stage BCMAxCD3 T-cell engager, to its pipeline, according to Gilead’s announcement. In practice, if the side deal now under discussion is finalized, Galapagos, the Belgian biotech that has been tied to Gilead since their sprawling 2019 alliance, would shoulder half the upfront and milestone bill, take on substantially all of Ouro’s operating assets and employees, and fund development through the start of registrational studies, according to a regulated disclosure from Galapagos. That is not standard biotech M&A. It is closer to Gilead buying control while outsourcing a meaningful slice of the operating burden.

That matters because autoimmune T-cell engagers are promising, but they are not exactly low-drama molecules. OM336 targets B-cell maturation antigen, or BCMA, and CD3, redirecting T cells toward antibody-producing cells that appear to drive some immune-mediated diseases. Ouro said in a January press release that it is studying gamgertamig in basket trials for autoimmune cytopenias including autoimmune hemolytic anemia and immune thrombocytopenia, as well as in Sjögren’s disease and idiopathic inflammatory myopathy, with subcutaneous dosing and a so-called detuned CD3 arm designed to reduce cytokine induction without losing too much potency, according to Ouro Medicines. That is the kind of engineering detail that tells you everyone involved knows the oncology version of this playbook can get hairy fast.

Gilead’s own language is bullish to the point of needing a raised eyebrow. The company said OM336 has shown “transformative efficacy” and a differentiated safety profile after a single treatment cycle in ongoing Phase 1/2 studies, according to the company release. Galapagos used much the same phrasing in its disclosure. What neither company disclosed in those announcements was the full underlying dataset. So the right read here is not that Gilead has bought a de-risked autoimmune franchise. It is that Gilead is paying now for the possibility that short-course plasma-cell depletion could produce the kind of durable, drug-free remission autoimmune drug developers have been chasing for years and describing with increasingly poetic synonyms.

Reuters, which reported the transaction at up to $2.18 billion including milestones, added little beyond the headline terms, but its coverage underscores how unusually large the check is for a private company at this stage and how quickly the deal was framed as a major portfolio move for Gilead rather than a niche bolt-on, according to Reuters. The strategic logic is easier to see when Galapagos enters the frame. Under the contemplated collaboration, Gilead would keep worldwide commercialization rights outside Greater China, where Keymed Biosciences already holds rights, while paying Galapagos a 20 percent to 23 percent royalty on net sales, according to Galapagos’ disclosure. In other words: Gilead wants the product and the commercial control. Galapagos would take much of the development and organizational load.

There is another layer here, and it is pure partnership archaeology. Galapagos said the new arrangement would also amend its legacy Option, License and Collaboration Agreement with Gilead to free up as much as $500 million of Galapagos cash for uses outside that pact, including as much as $150 million for share repurchases. That carveout only makes sense in the context of the original 2019 Gilead-Galapagos agreement filed with the U.S. Securities and Exchange Commission, which set up a broad co-development and option structure between the two companies. The Ouro transaction is therefore doing two jobs at once: pulling an autoimmune asset into Gilead’s orbit and quietly renegotiating some of the financial geometry of a partnership that has looked increasingly awkward over time.

The caveat, and it is a real one, is that Galapagos said these partnership terms remain in advanced discussions, not final. If that changes, the story changes with it. But if the framework holds, Gilead has found a distinctly 2026 biotech way to buy an asset: pay like it is an acquisition, operate it like a collaboration, and use the transaction to tidy up an older alliance while you are there. The next thing to watch is not just whether the deal closes, but whether OM336’s promised immune-reset story survives fuller data and whether this oddly elegant, slightly Rube Goldberg financing structure becomes a one-off or a template. In biotech, when the mechanism and the cap table are both complicated, assume both complications matter.